Sign Up Today and Learn More About Bonum Therapeutics Stock
Invest in or calculate the value of your shares in Bonum Therapeutics or other pre-IPO companies through EquityZen's platform.
Bonum Therapeutics Stock (BONT)
Bonum Therapeutics creates a technology platform to treat a wide range of diseases.
About Bonum Therapeutics Stock
Founded
2021
Headquarters
Seattle, WA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Bonum Therapeutics Press Mentions
Stay in the know about the latest news on Bonum Therapeutics
Seattle Biotech Uses AI to Speed Up Drug Discovery Advances
webpronews • Oct 13, 2025
USPTO Grants Key Mechanism of Action Patent to Bonum Therapeutics for its Conditionally Active Biologics Technology
biospace • Aug 14, 2025
USPTO Grants Key Mechanism of Action Patent to Bonum Therapeutics for its Conditionally Active Biologics Technology
businesswire • Aug 14, 2025
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
businesswire • Jun 10, 2025
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
biospace • Jun 10, 2025
Bonum Therapeutics Management
Leadership team at Bonum Therapeutics
Founder and CEO
John Mulligan
Board Member
Nicholas Walrod
Join now and verify your accreditation status to gain access to:
- Bonum Therapeutics Current Valuation
- Bonum Therapeutics Stock Price
- Bonum Therapeutics Management
- Available deals in Bonum Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Bonum Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Bonum Therapeutics Revenue and Financials
- Bonum Therapeutics Highlights
- Bonum Therapeutics Business Model
- Bonum Therapeutics Risk Factors
- Bonum Therapeutics Research Report from SACRA Research
Trading Bonum Therapeutics Stock
How to invest in Bonum Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Bonum Therapeutics through EquityZen funds. These investments are made available by existing Bonum Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Bonum Therapeutics stock?
Shareholders can sell their Bonum Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 430K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
